Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicityArticle Published on 2022-10-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-receptor-binding domain antibody Antibody titer binding antibody BNT162b2 booster dose ChAdOx1 comparable COVID-19 delta variant domain dose enrolled evaluated geometric geometric mean titer group groups HCW HCWs healthcare worker Heterologous heterologous vaccination homologous humoral immune response Humoral response immunogenicity induce Local Neutralizing antibody response Neutralizing antibody titer participant RBD reactogenicity reactogenicity profile reduced robust SARS-CoV-2 SARS-CoV-2 spike protein significantly higher systemic reactogenicity tolerable vaccination variant wild-type SARS-CoV-2 [DOI] 10.1016/j.cmi.2022.04.019 PMC 바로가기
Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assaysArticle Published on 2022-10-012022-11-15 Journal: Journal of Clinical Virology [Category] COVID19(2023년), SARS, 진단, [키워드] Abbott Abbott SARS-CoV-2 IgG acute respiratory syndrome addition antibody antibody assay Antibody concentrations assays binding antibody unit coefficient comparable Concentration Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) Coronavirus-2 correlated correlation epidemiological purposes geometric indicated material Patient Pearson Quantitative Quantitative SARS-CoV-2 antibody assay ranged Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein sera Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Siemen Siemens Spike protein The diagnostic sensitivity the SARS-CoV-2 the WHO was determined WHO [DOI] 10.1016/j.jcv.2022.105269 PMC 바로가기
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in JapanArticle Published on 2022-09-092022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] Abbott acute respiratory syndrome Adults age anti-RBD Anti-RBD antibody anti-RBD antibody response anti-receptor-binding domain anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 S antibody Antibody Response Antibody titer Architect Architect SARS-CoV-2 IgG II Quant assays blood sample BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine collected comparable Coronavirus-2 correlation dose Elecsy Elecsys Elecsys Anti-SARS-CoV-2 S evaluated first vaccination geometric GMT GMT ratio GMTs healthcare healthy immunoassay immunoassays Japan Kinetics mRNA vaccine no significant difference Older age Participants prospective cohort study RBD Roche Diagnostics SARS-CoV-2 SARS-CoV-2 IgG second vaccination Sex significantly lower Spearman vaccination were measured [DOI] 10.1016/j.vaccine.2022.08.018 PMC 바로가기
Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational studyObservational Study Published on 2022-09-022022-10-05 Journal: PLoS ONE [Category] SARS, 임상, 진단, [키워드] adverse event Anaphylactic reaction antibody BNT162b2 combination therapy COVID-19 COVID-19 pandemic dose Efficacy and safety eligible patient evaluate evaluated event geometric group Health immunosuppressive indicated Inflammatory bowel disease Local majority MONITOR Patient patients Prospective prospective observational study SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 vaccination significant difference therapy treated U/mL vaccination vaccination against COVID-19 Vaccine vaccine administration [DOI] 10.1371/journal.pone.0273612 PMC 바로가기 [Article Type] Observational Study
A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipientsBNT162b2 mRNA 백신의 세 번째 접종은 간 이식 환자의 면역 반응을 크게 향상시킵니다Article Published on 2022-09-012022-09-12 Journal: Journal of hepatology [Category] Fulltext, MERS, 진단, [키워드] Adverse adverse effect adverse effects age Anti-RBD IgG anti-SARS-CoV-2 antibody Antibody Response binding domain BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine Booster vaccine cellular immune responses cellular response center correlated determine dose doses Effect evaluate evaluated Factor fatigue Follow-up geometric humoral humoral immune response IgG immune immune response Immunity Immunosuppression immunosuppressive medications IMPROVE inhibitor liver liver transplant recipients local pain majority male median age Mild monotherapy neutralizing antibody Older age Patient predict RBD recipient recipients reported response Side effect side effects BNT162b2 mRNA vaccine significantly solid organ transplant T-cell the patient third dose Treatment Vaccine vaccine dose [DOI] 10.1016/j.jhep.2022.03.042 PMC 바로가기 [Article Type] Article
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-AnalysisArticle Published on 2022-08-292022-11-15 Journal: International Journal of Environmental Research an [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome antibody booster booster dose Cohort studies collaboration coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccine effective Effectiveness evaluate events fatigue Fever geometric GMTs help heterogeneous Heterologous heterologous booster dose higher risk homologous homologous booster dose Hospital admission immunogenicity interferon malaise myalgia neutralizing antibody Neutralizing titer Odds ratio outcome public health reduce resource review Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant searched suggested symptomatic the vaccine vaccination Vaccine Vaccines variance model were used [DOI] 10.3390/ijerph191710752 PMC 바로가기
Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022Article Published on 2022-08-252022-11-15 Journal: Viruses [Category] SARS, 진단, 치료기술, [키워드] age anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-Spike IgG anti-spike IgG antibodies antibody average Blood Blood donors category Covering detectable estimate female geometric IgG IgG antibody IgG level incidence individual infected with SARS-CoV-2 Involving median P -value participant percentage Period proportion public health quantified remained required SARS-CoV-2 seropositive participant seropositive participants Seroprevalence undetectable vaccinated individual [DOI] 10.3390/v14091877 PMC 바로가기
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine RecipientsBNT162b2 또는 CoronaVac 백신 수혜자의 혈청에 의한 중증 급성 호흡기 증후군 코로나바이러스 2 오미크론 변이체의 중화Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antibody titer Antibody titers Beta Beta variant beta variants BNT162b2 CoronaVac coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta variants detectable Effectiveness elicited evade genome sequence geometric geometric mean GISAID database GMT GMTs Health Organization isolate Lineage Live virus microneutralization Mutation Nanopore nanopore sequencing neutralization Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer no significant difference not affect of BNT162b2 omicron Omicron variant Patient recipient recipients respiratory risk Risk assessment SARS-CoV-2 Sequencing sera severe acute respiratory syndrome Coronavirus significant difference significantly lower spike mutation strain Strains susceptibility TMPRSS2 Vaccine Vaccines variant variant of concern VeroE6 cells virus was determined whole genome sequence World Health Organization [DOI] 10.1093/cid/ciab1041 PMC 바로가기 [Article Type] Article
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohortVirus Watch 코호트의 SARS-CoV-2 항체 및 획기적인 감염Article Published on 2022-08-182022-09-12 Journal: Nature Communications [Category] SARS, 진단, [키워드] 95% confidence interval anti-S anti-S antibody antibody BNT162b2 booster vaccination Breakthrough infection ChAdOx1 clinically Cohort Course Delta Effectiveness Efficacy Evidence geometric hazard higher risk Increasing individual Infection nine Older protective effect provide Ratio reduced risk risk risk of infection SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 vaccine second dose Support the timing total effect Vaccine [DOI] 10.1038/s41467-022-32265-5 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial